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S U M M A R Y
Background: Breast implant infections are usually caused by Staphylococcus aureus and coagulase-
negative staphylococci. Gram-negative bacilli are rarely reported to be involved in breast implant
infections.
Methods: Thirty-seven cases of microbiologically conﬁrmed breast implant infection managed from
January 2008 to June 2012 in the study centre were reviewed, including 10 cases from the study centre
itself and 27 cases from private clinics in the region.
Results: The prevalence of breast implant infection in the study centre was 0.74% of breast implantation,
i.e., 3.23% in breast reconstruction for breast cancer and 0.27% in aesthetic breast augmentation
(p = 0.0002). Of the 37 cases, 30% had undergone radiotherapy and 11% had undergone a lymph node
dissection. S. aureus was identiﬁed in 18 cases, Gram-negative bacilli in 10 cases, coagulase-negative
staphylococci in eight cases, anaerobic bacteria in eight cases, and streptococci in three cases.
Pseudomonas aeruginosa was the second most commonly identiﬁed pathogen. Staphylococcus epidermidis
was the most frequent coagulase-negative Staphylococcus species. In addition to Propionibacterium
acnes and Actinomyces neuii, other facultative and strict anaerobic bacteria have not been reported
before, e.g., Bacteroides thetaiotaomicron, Corynebacterium simulans, Dermabacter hominis, Finegoldia
magna, and Peptoniphilus harei. Seventy-percent of cases were treated by immediate implant removal. All
cases treated only with antibiotics were treated with surgery at the second visit.
Conclusions: The microbiological epidemiology was noted by an increasing the proportion of Gram-
negative bacteria and anaerobic bacteria detected with the advent of MALDI-TOF MS and molecular
identiﬁcation for diagnosis.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Breast implant infection is a complication after breast
augmentation that occurs in 2–53% of cases.1,2 The incidence is
higher in breast reconstruction after surgery for breast cancer than* Corresponding author: Centre interre´gional de re´fe´rence des infections oste´o-
articulaires Me´diterrane´e Sud; Service des Maladies Infectieuses, Hoˆpital de la
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1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).in aesthetic breast augmentation.2–4 In previous years, common
pathogens of breast implant infection have been Staphylococcus
aureus and coagulase-negative staphylococci.2 Atypical mycobac-
teria have been reported as pathogens involved in many breast
implant infection outbreaks.5–9 Few studies have reported breast
implant infections caused by Gram-negative bacilli.2,10
There are some well known risk factors for breast implant
infection, including obesity, diabetes mellitus, renal failure, active skin
disorders, and tobacco use. The risk is increased in patients
undergoing mastectomy, axillary dissection, or chemotherapy, as
well as those who have undergone prior radiation treatment,
reoperations, operations lasting longer than 2 h, or drain placement.2ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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absence of scar discharge, purulent ﬂow, cellulitis, or abscesses.
Despite improvements in the recognition of breast implant
infections, management strategies vary widely across centres,
particularly with regards to the choice and duration of antimicro-
bial treatment and when to remove the breast implants.2 However,
some authors have reported one-time exchanges of the breast
implants using antibiotics.11
The early and accurate identiﬁcation of bacteria is a critical
requirement for prompt and appropriate antimicrobial treatment
of breast implant infections.12 The arrival of matrix-assisted laser
desorption/ionization time-of-ﬂight mass spectrometry (MALDI-
TOF MS) in the study centre has increased the speed and
identiﬁcation of the common and rare bacterial species involved
in human infection.13
In this study, the clinical and microbiological features of breast
implant infections managed in a regional referral centre for plastic/
reconstructive surgery in the south of France were reviewed
retrospectively.
2. Materials and methods
A review was performed of all breast implant infection cases
managed from January 2008 to June 2012 in a regional referral
centre for plastic/reconstructive surgery in the south of France. A
total of 1350 breast implant surgeries were performed in the study
centre during the study period, including 217 deﬁnitive implants
for reconstruction and 1133 aesthetic breast augmentations. The
study centre also supports patients with breast implant infections
for whom the breast implant surgery was performed in private
clinics in the region.
The following data were collected: patient clinical character-
istics (i.e., age, comorbidities, use of tobacco, previous radiothera-
py, adjuvant chemotherapy, and lymphadenectomy) and past
surgical history (i.e., aesthetic or reconstruction, type of incision,
and type of implant). The timing of onset of the infection, clinical
signs, and microbiological results were also recorded. An acute
breast implant infection was deﬁned by the appearance of clinical
signs 6 weeks after the implantation; a late breast implant
infection was deﬁned by the appearance of clinical signs >6 weeks
after the implantation.1,2 The antimicrobial and/or surgical
treatment approaches used in each case were reviewed. The
treatment outcome was evaluated at 3, 6, 12, and 24 months after
the end of treatment. This study was approved by the institutional
research ethics board and written informed consent was obtained
from each patient.
The diagnosis of breast implant infection was based on the
patient’s medical history, including clinical evidence of infection
from biological and/or radiological data, and at least two positive
cultures from deep surgical or percutaneous biopsy samples to
exclude contaminating bacteria, as described previously.13 After
incubation, the bacteria were identiﬁed through MALDI-TOF MS
(Bruker Daltonik), as described previously.13 Complete 16S rRNA
gene sequencing was performed for unknown anaerobic bacteria
not identiﬁed by MALDI-TOF MS, as described previously.13 The
antibiotic susceptibilities of bacterial isolates were determined
and interpreted according to the recommendations of the French
Society for Microbiology and the European Committee on
Antimicrobial Susceptibility Testing (http://www.
sfm-microbiologie.org/UserFiles/ﬁles/casfm/
CASFM_EUCAST_V1_0_2014.pdf). The susceptibility of Staphylo-
coccus isolates to methicillin was screened by agar diffusion using
cefoxitin disks (BioRad, Marnes-La-Coquette, France).
The antimicrobial and/or surgical treatment approaches used
and the ﬁnal outcome of each case were reviewed. Treatment was
considered successful when there was remission, i.e., thedisappearance of all breast infection symptoms after the end of
antibiotic treatment. Relapse was deﬁned by the reappearance of
active breast implant infection symptoms at any time following
treatment.
Data analyses were performed using IBM SPSS Statistics,
version 20.0 software (IBM Corp., Armonk, NY, USA). Proportions
were compared using the Chi-square test or Fisher’s exact two-
tailed test. A p-value of <0.05 was considered statistically
signiﬁcant.
3. Results
A total of 37 cases of microbiologically conﬁrmed breast
implant infection were managed in the study centre. Of the
37 breast implant infection cases, 14 (38%) had undergone breast
implant placement for reconstruction after breast cancer and 23
(62%) had undergone placement for aesthetic breast augmenta-
tion. Forty-eight percent of patients with aesthetic breast
augmentations had undergone repeat implant placement.
Ten breast implant infections involved patients from the study
centre, representing 0.74% of breast implantations; these included
seven cases (3.23%) of breast reconstruction for breast cancer and
three cases (0.27%) of aesthetic breast augmentation. The
prevalence of breast implant infection was signiﬁcantly higher
in the group of patients who had breast implants placed for
reconstruction after breast cancer (p = 0.0002). Twenty-seven
other breast implant infection cases were from private clinics in
the region, including seven cases in breast reconstruction for
breast cancer and 20 cases in aesthetic breast augmentation.
Silicone implants were used in 81% of cases, while saline serum
implants were used in 19% of cases. In all 37 cases, the breast
implants were inserted in the retromuscular space at the level of
the periosteum, through the inframammary fold in 50% of cases,
through the mastectomy incision in 32%, and by axillary incisions
in 18%.
The mean patient age was 44  14 years (range 19–76 years).
Eleven patients (30%) were tobacco users, 11 patients (30%) had
undergone radiotherapy for breast cancer, four patients (11%) had
undergone a lymph node dissection for breast cancer, one patient had
diabetes mellitus, two patients were on immunosuppressive therapy
and/or corticosteroid treatment, and one patient was HIV-positive
(Table 1).
Sixteen cases (43%) occurred at 6 weeks after the implantation
and 21 cases (57%) occurred >6 weeks after the implantation. The
median onset to diagnosis was 330 days (range 3–6120 days). Most
cases were paucisymptomatic and the main symptoms were
purulent ﬂow or scar distension, which was present in 17 of the
cases (46%), followed by abscess in 11 cases (30%), local cellulitis in
six cases (16%), and fever in seven cases (19%). Biological
parameters of inﬂammation, i.e., a high leukocyte count
(>12  109/l) and/or a high plasma C-reactive protein level
(>40 mg/ml), were recorded in ﬁve of the cases (13%). There were
four complications of breast implant infection: one toxic shock
syndrome associated with a breast implant infection due to
Streptococcus pyogenes and three cases of chronic rib osteomyelitis.
Among the 17 species of bacterial isolate (N = 47) involved in
breast implant infection, S. aureus was the most common,
identiﬁed in 18 cases (49%), followed by Gram-negative bacteria
in 10 cases (27%), coagulase-negative staphylococci in eight cases
(22%), strict anaerobic bacteria in ﬁve cases (14%), facultative
anaerobic bacteria in three cases (8%), and streptococci in three
cases (8%). The ﬁve strict anaerobic bacteria identiﬁed in this study
were Propionibacterium acnes, Bacteroides thetaiotaomicron, Fine-
goldia magna, and Peptoniphilus harei, and the three facultative
anaerobic bacteria identiﬁed were Dermabacter hominis, Coryne-
bacterium simulans, and Actinomyces neuii.
Table 1
Breast implant infections: comorbidities, clinical and biological presentations, and
related complications
Number
of cases
%
Pattern and type of breast implant prosthesis
Aesthetic reasons 23 62%
Repeat implant placement for aesthetic
breast augmentation
11 29%
Breast cancer 14 38%
Silicone implant 20 54%
Saline serum implant 7 19%
Unknown type of breast implant 10 27%
Comorbidity of breast implant infection
Prior radiotherapy 11 30%
Tobacco user 11 30%
Lymph node dissection 4 11%
Corticosteroid treatment or
immunosuppressive treatment
2 6%
Diabetes mellitus 1 3%
HIV 1 3%
Type of breast implant infection
Acute infection (6 weeks) 16 43%
Late infection (>6 weeks) 21 57%
Clinical and biological presentations
of breast implant infection
Purulent ﬂow or scar dissension 17 46%
Abscess 11 30%
Cellulitis 6 16%
Fever 7 19%
Leukocytosis >12  109/l or CRP >40 mg/ml 5 13%
Complications of breast implant infection 4 11%
Toxic shock syndrome 1 3%
Rib osteomyelitis 3 8%
CRP, C-reactive protein.
Figure 1. Bacterial species isolated 
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common pathogen species of breast implant infection in this study.
Seven (19%) of the breast implant infection cases were poly-
microbial. Only one bacterium (D. hominis) out of the 47 bacterial
isolates required identiﬁcation by 16S rRNA gene sequencing. The
bacterial species involved in the breast implant infections are
shown in Figure 1.
All 18 of the S. aureus isolates were methicillin-sensitive
S. aureus (MSSA). Of the eight coagulase-negative Staphylococcus
isolates, only two Staphylococcus epidermidis were resistant to
methicillin, whereas three S. epidermidis isolates, two Staphylococ-
cus lugdunensis isolates, and one Staphylococcus simulans isolate
were susceptible to methicillin.
Eleven cases (30%) of breast implant infection were treated with
an antibiotic regimen without immediate implant removal;
26 cases (70%) were treated with immediate implant removal.
Surgical debridement consisted of a ﬁstulectomy and removal of
the necrotic tissues, leaving only good quality tissues. The
periosteum and perichondrium was later followed to avoid
exposing the pleura and mediastinum.
All 11 cases treated initially with only antimicrobials were
subsequently treated with surgery. One patient was treated with a
one-stage prosthesis exchange and another patient was treated
with a salvage attempt consisting of prosthesis removal and
compartment cleaning. Both of these patients relapsed and
required complete removal of the implant.
The main antibiotic treatment in the postoperative period was
amoxicillin–clavulanic acid (22 cases), followed by a combination
of ceftazidime or piperacillin/tazobactam and ciproﬂoxacin (eight
cases), a combination of rifampicin–oﬂoxacin (four cases), co-
trimoxazole (one case), a combination of co-trimoxazole and
clindamycin (one case), and amoxicillin (one case). The meanfrom breast implant infections.
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days). With regard to complications of breast implant infections, there
were three cases of costal osteomyelitis, which were treated with
90 days of antibiotherapy. New prostheses were successfully placed in
16 cases. The median time to the new placement was 228 days. The
mean duration of follow-up was 331  231 days (range 60–810 days).
No relapses were observed during the follow-up period.
4. Discussion
This study investigated 37 cases of microbiologically proven
breast implant infection that represented 2.74% of breast
implantations managed during the study period of 4.5 years.
The breast implant infection rate was found to be signiﬁcantly
higher in breast reconstruction after mastectomy for breast cancer
than aesthetic breast augmentation in this series (6.45% vs. 2.03%,
p = 0.001). Infection rates after aesthetic breast augmentation
reported in the literature vary from 2% to 2.5%;2,14–16 the average
infection rate after mastectomy for breast cancer has been
reported to be 5.8% (range 0–29%).17 Some authors have recorded
a higher rate, ranging from 47% to 53% of breast implant
procedures.18,19
With regard to the classical risk factors for breast implant
infection, such as diabetes mellitus, tobacco use, and immunode-
ﬁciency,4,20 30% of cases in the present study had undergone
radiotherapy and 11% had undergone a lymph node dissection for
breast cancer. Nevertheless the most important risk factor
observed was repeat implant placement for aesthetic breast
augmentation (29%). Breast implant infections are usually reported
as early infections, frequently occurring at <6 weeks after the
implantation.1 Surprisingly, it was found that 57% of cases in the
present study occurred at 6 weeks after the implantation. This
may be explained by the higher number of breast implant
infections in patients presenting from the private clinics in the
region (17 cases) compared to inpatients (ﬁve cases). No risk factor
or bacterial species was identiﬁed that was signiﬁcantly associated
with the time elapsed between placement of the breast implant
and infection.
S. aureus remains the most frequent pathogen identiﬁed in breast
implant infection: 49% in the present study and 67% in the
literature.21 However, Gram-negative bacilli that have been
considered uncommon pathogens of breast implant infections2,21
were found in 27% of cases in the present series. A higher proportion
(42–44%) of Gram-negative bacilli has been reported recently in
breast implant infection after surgical reconstruction in patients
with breast cancer.10,22 No signiﬁcant difference in Gram-negative
bacilli between breast implant infections after surgical reconstruc-
tion in patients with breast cancer compared with breast implant
infections after aesthetic breast augmentation were found (3/14 vs.
7/23, p = 0.7099). It was found that Gram-negative bacilli breast
implant infections were not signiﬁcantly involved in late infections
compared to acute infections (7/21 vs. 3/16, p = 0.4613).
Of the coagulase-negative staphylococci involved in breast
implant infections, S. epidermis was the most common pathogen,
identiﬁed in 14% in the present series and in 19.2–67% in previous
studies.19,23 A few cases of breast infection caused by S. lugdunensis
after plastic surgery, e.g., mammoplasty and mastectomy for
breast cancer, have been reported.24–27 Moreover, S. simulans,
which was identiﬁed in one of the present breast implant infection
cases, has not been reported in the literature.
Eight facultative and strict anaerobic bacteria involved in breast
implant infections were identiﬁed in this study. Among them,
P. acnes has been reported in 27.3% of breast implant infections.19 A
few cases of breast implant infection caused by A. neuii28 and
Corynebacterium species have been reported.29 Nevertheless,
breast implant infections caused by B. thetaiotaomicron, C. simulans,D. hominis, F. magna, and P. harei have not been reported. No
association was found between bacterial species and the risk factors
in this study.
The lack of a comparison with previous data on the microbial
epidemiology of breast implant infections before the arrival of
MALDI-TOF MS in the study centre to conﬁrm this changing
epidemiology of breast implant infection is one of the limitations
of this study. Nevertheless, 98% of 47 bacterial species involved in
breast implant infections in this series were identiﬁed by MALDI-TOF
MS; only one bacterial species ‘Dermabacter hominis’ required
molecular identiﬁcation. In addition, MALDI-TOF MS allowed the
early and accurate identiﬁcation of anaerobic bacteria involved in the
cases of breast implant infection in this study; the technique has been
used successfully in the identiﬁcation of unknown anaerobic bacteria
involved in osteoarticular infections in previous studies.13,30
Ninety-two percent of Staphylococcus isolates in this study
were susceptible to methicillin, which is lower than the percentage
reported in previous studies.11,21 In this study, the presence of
Staphylococcus isolates resistant to methicillin and an increase in
the proportion of Gram-negative and anaerobic bacteria were
noted. We do not recommend speciﬁc empirical antibiotic
treatment before bacterial species identiﬁcation and the results
of susceptibility testing are known.
Surgical removal of the implant is required in most cases of
breast implant infection; a two-stage breast prosthesis replacement
is usually recommended.2,31 Some studies have reported successful
one-stage prosthesis exchange or salvage attempts, consisting of
prosthesis removal and cleaning of the compartment.32–34 The
reported success rate of early salvage followed by one-stage
prosthesis exchange in cases of breast infection that are not too
severe is in the range of 45% to 76.7%.32–34 Two of the cases in the
present series treated by salvage without implant removal both
relapsed and required complete implant removal. Due to the lack of
randomized controlled trials, we do not recommend one-stage
prosthesis exchange in severe cases of breast implant infection.
In conclusion, breast implant infection rates after cosmetic
augmentation are low, unlike the higher rates after breast
reconstruction following mastectomy for breast cancer. The most
important risk factor observed was repeat implant placement for
aesthetic breast augmentation. With regard to the microbiological
epidemiology, an increasing proportion of Gram-negative bacteria
and anaerobic bacteria detected with the advent of MALDI-TOF MS
and molecular identiﬁcation for diagnosis was noted. The
remission rate for this condition is high, nevertheless severe and
rare complications such as toxic shock syndrome and rib
osteomyelitis may occur. Breast implant infections require a
multidisciplinary approach to improve the prognosis, and the
management consists of implant removal and antibiotics selected
according to the microbiological surgical sample results.
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